Coverage continuity is becoming a core operational competency in Medicaid.

The Medicaid unwinding exposed how much coverage depends on paperwork, notices, documentation, and verification rather than eligibility itself. Federal policy is now increasing the number of moments where members must successfully navigate those processes. Six-month renewals begin for expansion populations in 2027. Work requirements introduce another layer of verification. States, plans, and providers face a growing volume of administrative decisions tied directly to enrollment, reimbursement, and member retention.

Fortuna Health sits squarely in that emerging category. The company helps members complete renewals, gather documentation, respond to notices, maintain eligibility, and move through administrative processes that increasingly determine whether coverage continues. Its product combines eligibility screening, document collection, multilingual support, renewal workflows, notice management, and closed-loop reporting into a single operating layer designed around coverage continuity.

Medicaid retention infrastructure addresses a problem already measured in millions of disenrollments and billions of dollars in reimbursement exposure. Every completed renewal preserves member months. Every restored eligibility determination reduces coverage disruption. Every successful documentation workflow lowers the probability of administrative churn.

Fortuna remains an early company. Most publicly available outcome data originates from company-published case studies and customer examples rather than independent evaluations. The strongest evidence today supports the category itself: procedural disenrollment remains widespread, verification requirements are increasing, and healthcare organizations need better ways to manage administrative complexity at scale.

Fortuna offers one of the clearest early expressions of this category. The remaining question is whether the company can translate category momentum into durable procurement, measurable outcomes, and contract renewals.

Why this category matters now

Coverage continuity has become one of the most important operational challenges in Medicaid.

The Medicaid unwinding revealed how much coverage depends on paperwork, notices, documentation, address accuracy, and renewal completion. KFF estimates that 69% of disenrollments during unwinding were procedural, leaving millions of eligible people without coverage because administrative requirements were not completed successfully.

Federal policy is increasing the number of opportunities for those failures to occur. Adult expansion populations move to six-month renewals beginning January 1, 2027. Medicaid work requirements add additional verification obligations for affected populations. States must collect documentation, process renewals, determine exemptions, verify compliance, and communicate requirements across large and often difficult-to-reach populations.

For Medicaid plans, procedural churn translates into lost member months, disrupted attribution, interrupted care-management relationships, and higher reacquisition costs. Providers face rising self-pay exposure when coverage lapses. States inherit larger administrative workloads, increased call-center volume, implementation risk, and greater pressure to process eligibility actions accurately and on time.

The economic exposure is straightforward: eligible people lose coverage because the system cannot successfully move information from one place to another.

Fundable 15 score: 25 / 31
Recommendation: Partner / Pilot
Category: Financial Contracting Innovation
Buyer: Medicaid MCOs, providers, health systems, state/county agencies, risk-bearing organizations

POLL RESULTS

Subscribe now

Read more

NourishedRx is one of the more operationally mature Food-as-Medicine companies because its model is structured around payer integration, condition-specific nutrition support, and benefits orchestration rather than standalone food delivery. The company combines medically tailored meals, groceries, registered dietitian support, wellness associates, FHIR-enabled interoperability, and payer/provider workflow integration, omnichannel engagement, continuous monitoring, registered dietitian support, actionable care-gap escalation, and FHIR-enabled interoperability. That positioning aligns directly with the procurement pressures shaping the next phase of Food-as-Medicine adoption, including HRSN operationalization, supplemental-benefit oversight, encounter integrity, auditability, renewal defensibility, and measurable integration into payer operations. As procurement standards tighten, the strongest organizations are increasingly the ones capable of delivering nutrition interventions within existing healthcare infrastructure while maintaining operational, financial, and governance alignment.

This analysis represents the author’s interpretation of publicly available information. All forward-looking assessments involve uncertainty and risk. Readers should conduct independent research and consult qualified professionals before making business or investment decisions.

THESIS

NourishedRx gives plans and providers a scalable operating layer for deploying nutrition interventions inside existing chronic-disease, maternal-health, and utilization-management workflows.

This is materially different from pantry-style food access, generalized wellness nutrition, standalone grocery cards or community-food narrative programs.

The company’s strongest differentiator is operational integration and workflow infrastructure rather than meal delivery alone.

Publicly available materials increasingly support this interpretation through:

• payer-integrated workflows

• reporting feeds

• escalation pathways

• continuous engagement infrastructure

• personalized deployment logic

• care-gap integration

• longitudinal measurement architecture ↴

EVIDENCE

NourishedRx’s strongest public signals center on operational sophistication, payer integration, longitudinal engagement infrastructure, and directional utilization relevance. Across CHF, diabetes, and maternal-health deployments, the company demonstrates the ability to operationalize nutrition interventions inside healthcare workflows, sustain participation longitudinally, integrate with payer quality and reporting structures, and expand beyond pilot-stage deployment. Taken together, these signals support operational maturity, procurement relevance, and directional utilization plausibility more strongly than independently validated actuarial-grade certainty.

Sources: [Maternal Health] [Diabetes] [CHF]

PMPM RECONSTRUCTION

SO, HOW DOES FIM ACTUALLY MAKE IT TO $474 PMPM IN COST SAVINGS?

Read more

As Medicare Advantage and Medicaid plans enter 2026 renewal and rebid preparation, post-acute utilization is being evaluated as a single operational exposure—readmissions, FUH performance, and SNF utilization assessed together rather than in isolation. Models that govern authorization timing, site-of-care selection, and network execution are increasingly central to how margin stability and quality outcomes are underwritten for the next contract cycle.

CareCentrix sits directly inside that decision path.

THIS IS THE FUNDABLE 15

CareCentrix

Category: Post-Discharge Stabilization

Model Type: Delegated post-acute care coordination platform

Headline math: Post-acute execution governance delivers net-neutral to +$150 PMPM margin defense in Year 1 under conservative assumptions, with upside driven by SNF day compression and avoided readmissions

Utilization impact (directional):
ED revisits ↓ 10–15%
Readmissions ↓ 8–12%
SNF days ↓ 15–25%

Decision window: 2026 MA / Medicaid renewals where FUH, readmissions, and SNF exposure are reviewed together — not measure by measure

“Go now” environments:
Markets with delegated post-acute authority already in place (MA national books; Medicaid MCOs with centralized UM and SNF exposure)

This analysis represents the author’s interpretation of publicly available information. All forward-looking assessments involve uncertainty and risk. Readers should conduct independent research and consult qualified professionals before making business or investment decisions.

CareCentrix’s competitive advantage is rooted in enabling care to start correctly from the outset.

By intervening at the moment when utilization is determined they ensure follow-up unfolds on a solid foundation.

This upstream precision drives reliable continuity, reduces downstream friction, and sustains consistent care delivery at scale.

Subscribe now

IN THIS EDITION

• Execution-to-claims evidence linking post-acute control to utilization outcomes

• Interpretive scorecard outlining strengths, constraints, and conservative assumptions

• Delegated-model economics clarifying replacement versus incremental spend

• Accounting treatment across MA, Medicaid, and ACO risk structures

• 30–90 Day Utilization Math

• Operational guardrails defining renewal-safe attribution boundaries

• Buy / Partner / Pilot / Wait posture by operating environment

• Fundable verdict with a bounded bear case

Read more

As CMS prepares to open a 10-year payment pathway for technology-supported chronic care through the ACCESS Model, musculoskeletal (MSK) pain has emerged as one of the first—and most conservative—clinical categories Medicare appears willing to underwrite in Original Medicare.

That distinction matters.

Among the crowded field of MSK vendors, Hinge Health stands out not because it is the most technologically advanced platform, but because it already operates in a form Medicare can audit, defend, and scale.

In the early phases of ACCESS, structure may matter more than innovation.

WHY THIS MATTERS NOW

Beginning July 1, 2026, CMS will begin issuing predictable, outcome-aligned payments for chronic care programs that meet a narrow set of requirements, including:

• Validated patient-reported outcome measures (PROMs)

• Clear primary-care co-management

• Defined clinical governance and accountability

• Audit-legible documentation

Chronic musculoskeletal pain is explicitly named as a core ACCESS track. That designation shifts the market conversation from which MSK vendor delivers the best outcomes to a more operational question:

Which organizations are structurally legible to Medicare as care delivery entities?

WHY MSK

CMS did not pick MSK at random.

An estimated 36–40% of Medicare beneficiaries experience chronic pain, most commonly musculoskeletal and often across multiple sites. MSK pain is also a major upstream driver of high-cost Part A and Part B utilization: imaging, procedures, opioid prescribing, and avoidable surgery.

States and Medicare Advantage plans have already been moving toward conservative-first MSK pathways through bundles, utilization controls, and escalation limits. ACCESS formalizes this shift, creating a bounded, longitudinal payment lane designed to reduce escalation rather than manage downstream damage.

From a program design perspective, MSK represents one of the lowest-risk entry points for CMS’s most significant chronic-care payment expansion in a decade.

WHERE THE DIFFERENTIATION SHOWS

The MSK market includes several operators with strong outcomes, licensed clinicians, validated PROMs, and credible ROI data.

Read more

Company: Bamboo Health, a behavioral data-exchange infrastructure company.

Category: Tech-Enabled

Score: 22 / 31 → Procurement-Ready Band. See the current Fundable 15.

Market Signals to Watch

• HTI-1 Implementation (2025 → 2026): ONC mandates cross-system data exchange — making Bamboo’s alert feeds a compliance necessity.

• Stars Recalibration (2026 cycle): FUH and FUA maintain 3× weight under CMS 4201-F → direct margin pressure.

• State Withhold Expansion: Indiana, Arizona, and Kentucky renew 2–3% behavioral withhold pools (≈$100M+ recoverable across markets).

• Behavioral Crisis Modernization: OpenBeds links 988 and jail-diversion networks → permanent interoperability layer.

• Investor Shift: Capital moves from behavioral apps to behavioral data rails — policy-anchored, utility-style returns.

The Model

How Bamboo Health Makes Money / Saves Margin

Read more

1. Nurse-Family Partnership (Changent) — 29 / 30
   Category: Special Populations
   Maternal & early-childhood health (CBO model).
   RCT-validated ROI reducing NICU and child-protective events; multi-state Medicaid contracts and claims-verified outcomes.

   Scorecard

2. Netrin Health — 25 / 30
   Category: Financial Contracting Inno…

Read more

For high-risk CHF, COPD, and DM members, DispatchHealth cuts 30-day readmits ≈ 50%, lifts FUH and TRC scores, and defends Stars and withhold margin in a post-waiver world.

Update: October 10, 11:17 PST

On Fierce Healthcare interview, DispatchHealth has publicly accepted that the waiver expiration has real friction and disruption, but they position their model as relatively insulated and emphatic that many functions continue unaffected.

The update generally supports our thesis that durable models outlast temporary policy shifts. Their operations show that core demand, not regulatory permission, drives viability.

Why it matters:

As of 2025 Stars, CMS has:

• Reduced the weight of experience/access measures from 4× → 2× starting CY 2026 (Avalere 2025)

• Tightened improvement bonuses under the new EHO4All equity framework (effective 2027)

• Maintained FUH, TRC, and readmission-related metrics as the only remaining high-weight (3×) levers plans can influence operationally within one Stars cycle

In-home acute care is one of the few interventions that simultaneously moves all three:

1. FUH / TRC → immediate lift in measure completion

2. Readmits / TCOC → margin defense and withhold recovery

3. CAHPS trust → direct patient-experience boost (Dispatch NPS 97)

That makes it one of the last controllable Stars levers now that the waiver has closed and telehealth flexibilities are retracted.

ROI at a Glance

Where DispatchHealth Protects Margin

≈ 50% fewer 30-day readmissions (n > 1,000 patients)

≈ 15–30% total cost reduction (modeled payer data; MedPAC 2024)

Each 0.1 Stars lift = ≈ $8–$10M margin gain / 100K members → $25–$40M recoverable value.

Decision Window (Oct–Dec 2025)

GO: Plans finalizing FUH, TRC, CAHPS files before Nov 15 lock (≈ 30 days).

POSITION: Vendors with encounter-ready data and Stars lift proof.

WAIT: Tech-only entrants without claims pathways → prep for 2026 Stars cycle.

In This Edition

Free: Stars math, ROI signal, and policy framing.

Paid (Full Deck): Evidence-Bar table | Withhold math (Indiana - Illustrative) | CFO Accounting Map | Ops SLA metrics | Stress-Test Q&A.

Analysis based on publicly available sources and Fundable 15 pre-actuarial modeling. Forward-looking assessments carry risk. Not an actuarial opinion under ASOP #41 or #49.

This is the Fundable 15

Subscribe now

Deck [Downloadable]

Read more

Entity: MassHealth; MA plans; HRSN operators

What was wrong: MTM adoption occurred, but much more slowly and unevenly, with HRSN used as a controlled release valve, not a growth accelerator.

Why wrong: I treated lane clarity as demand, when it functioned as permission without urgency.

Impact: Overestimated near-term velocity of MTM market expansion.

This week’s spotlight: Community Servings: Medically Tailored Meals deliver net $220 PMPM margin defense

In This Edition

• Headline math: $220 PMPM net savings (Health Affairs 2018; JAMA IM 2019)

• Readmits ↓ ≈49%; SNF utilization ↓ ≈72%

• “Go now” states: CA, MA, OR, NC (clear HRSN/ILOS lanes)

• What’s new about this story

For Paid Subscribers

• Evidence-Bar table with peer-reviewed anchors (Health Affairs, JAMA IM, MA HRSN 2025)

• Coding & pricing anchors: CA/MA fee schedules, NC HOP rates

• Ohio (illustrative teaching example) withhold math: how MTM could earn back up to $4.96M in adult preterm-birth slice capacity—method transferable

• CFO Accounting Map: where costs/savings book for Medicaid, MA, and ACOs

• SLA & duplication controls (activation ≤72h, audit rules)

• Stress-test: Q&A

This analysis represents the author’s interpretation of publicly available information. All forward-looking assessments involve uncertainty and risk. Readers should conduct independent research and consult qualified professionals before making business or investment decisions.

MTM for high-risk CHF/CKD/DM cuts readmits and SNF use and delivers a median net $220 PMPM (Health Affairs 2018 matched analysis) — defending Medicaid MLR/withholds and MA/ACO total cost of care.

Math Bar

• Net $PMPM (median): $220 (post-program, matched analysis) Health Affairs

• Readmits ↓ ≈49% (observational/matched; IP IRR≈0.51) JAMA Network

• SNF utilization ↓ ≈72% (observational/matched; SNF IRR≈0.28) JAMA Network

Decision Window (6–12 months):

Go now: CA / MA / OR / NC (clear HRSN/ILOS lanes) DHCS

Position: OH (illustrative payout math below), FL / TX / AZ / IN (run MA supplemental or ACO risk until HRSN formalizes)

Buy / Partner / Pilot / Wait:

• Partner now: Medicaid plans in lane states; D-SNP/MA plans with readmit hot-spots; ACOs with SNF leakage

• Pilot: 30/90-day discharge hedge with activation ≤72h and outcomes guarantees

• Wait: States without a lane and no hospital MOU

This is the Fundable 15

Subscribe now

Also for you:

• I built a Social Care Impact Quick Guide + bonus training video — a simple framework any department can use to translate frontline actions into measurable ROI, conservatively protecting $250K/year at the unit level.

  Early adopter pricing: $10, capped at the first 100 → Get it here.

Why this isn’t another “meals” story

• Evidence with deltas that survive audit (observational/matched; peer-reviewed): IP IRR≈0.51, SNF IRR≈0.28, monthly cost ≈−16% with IP/SNF the main driver; net $220 PMPM after program cost.

• Contractable today: CA Community Supports (MTM/MSF), MassHealth HRSN (fee schedule + claims rules), Oregon HRSN (clinical eligibility), North Carolina HOP (fee schedule).

Read more

Entity: California DHCS; Medi-Cal MCPs

What was wrong: No plan-level or statewide denial-rate tables were published in 2026. DHCS acknowledged denials qualitatively but did not release quantitative comparatives.

Why wrong: I assumed importance would force publication. It did not.

Impact: Readers expecting confirmatory data would have waited for proof that never came.

Additionally, parts I & II claimed NICU utilization avoidance would emerge as a public plan-level KPI or EQR table, validating maternal intervention ROI.

Entity: Nevada Medicaid; SilverSummit; DHCS/DHCFP

What was wrong: NICU utilization never appeared as a public plan-level KPI in EQRs or dashboards. It remained governed and authorized, but unpublished.

Why wrong: I assumed measurement follows economic importance. In reality, measurement followed political safety.

Impact: Overstated the likelihood of external NICU validation.

This analysis represents the author’s interpretation of publicly available information. All forward-looking assessments involve uncertainty and risk. Readers should conduct independent research and consult qualified professionals before making business or investment decisions. This content is for informational purposes only.

In This Edition:

• Why maternal health now

• Scorecard: 8 orgs ranked

• Market signals: CA denials, NM SPA, DC renewals

• Tier updates: SisterWeb, Centering, Mamatoto, Commonsense, Bloomlife, Tewa, BLA

Premium:

• Full scores (0–100) + fundability tiers

• Play Boxes: payer + investor actions

• Contract clauses in procurement

• Heat map: NICU, Stars, audit durability

• Outlook: who to buy, pilot, or wait on

In maternal health, the market is full of promises: SPAs approved, press releases issued, glossy equity reports circulated. But as Angelou reminds us, evidence is the truth-teller. If an organization can’t show claims-paid outcomes, executed contracts, or workforce throughput today, don’t expect it to tomorrow.

Edition 1 covered the procurement-ready leaders with contracts and claims on file.

Edition 2 turns to the next wave community-rooted and equity-first models now testing Medicaid’s SPA lanes.

Recap: Here are the maternal models reshaping Medicaid, Stars, and ROI in late 2025.

For a breakdown on #1-7, check out Part I.

Market Signals to Watch

• California: Doula SPA live; early denials surfacing.

• New Mexico: SPA NM-24-0004 approved; reimbursement details hidden in MCO addenda.

• DC: CHA FY25 renewal delayed → Mamatoto exposure.

• San Francisco: SisterWeb contracts under SFDPH review; CDI flagged in AMCHP pipeline.

• National: MCOs tying Stars bonuses + postpartum adherence withholds into contracts.

Fundability Tiers (Edition 2)

• Tier 1 (≥75): Procurement-ready → SisterWeb, CenteringPregnancy

• Tier 2 (60–74): Pilot-worthy → Mamatoto, Commonsense, Bloomlife

• Tier 3 (<60): Watchlist → Tewa Women United, BabyLiveAdvice, HealthConnect One

Upgrade now to unlock the complete profiles and playbooks.

Subscribe now

Read more

Entity: California DHCS; Medi-Cal MCPs

What was wrong: No plan-level or statewide denial-rate tables were published in 2026. DHCS acknowledged denials qualitatively but did not release quantitative comparatives.

Why wrong: I assumed importance would force publication. It did not.

Impact: Readers expecting confirmatory data would have waited for proof that never came.

Additionally, parts I & II claimed NICU utilization avoidance would emerge as a public plan-level KPI or EQR table, validating maternal intervention ROI.

Entity: Nevada Medicaid; SilverSummit; DHCS/DHCFP

What was wrong: NICU utilization never appeared as a public plan-level KPI in EQRs or dashboards. It remained governed and authorized, but unpublished.

Why wrong: I assumed measurement follows economic importance. In reality, measurement followed political safety.

Impact: Overstated the likelihood of external NICU validation.

This analysis represents the author’s interpretation of publicly available information. All forward-looking assessments involve uncertainty and risk. Readers should conduct independent research and consult qualified professionals before making business or investment decisions. This content is for informational purposes only.

In This Edition:

• Why maternal health now

• Scorecard: 7 orgs ranked

• Evidence vs PR lesson

Premium:

• $95M–$125M ROI bands

• County-level Stars signals

• Risk & headwinds dashboard

• Vendor playbooks (payer + investor)

• Heat map: fundability at a glance

Also for you:

• How early investments in wraparound prenatal to postpartum supports improve outcomes while lowering costs.

• From logical fallacies to the Cobra Effect: A 360° view on accounting for 3am social interventions

Why Maternal Health, Why Now

By late 2025, maternal health has moved from the sidelines of public health to the frontline of healthcare finance, compliance, and survival.

• Politics: Persistent maternal mortality gaps , especially for women of color, have placed Medicaid agencies and MCOs under a spotlight in the H.R.1 era. Maternal equity is now a test of political credibility and procurement logic.

• Finance: NICU admissions, avoidable C-sections, and postpartum complications are among the most expensive and preventable events in care delivery. Every missed prenatal visit or failed postpartum follow-up shows up as direct margin erosion.

• Compliance: Maternal outcomes are now hardwired into HEDIS, Stars, CAHPS, and state reprocurements. Miss them, and plans risk billions in renewal revenue and contract retention.

This report began with a blunt directive: identify the maternal health-aligned organizations most exposed to OBBA and Q3–Q4 2025 policy shocks including those required to prove ROI, withstand MLR scrutiny, and survive funding disruptions.

We focused on three categories of players:

• Funder-facing grantees (home visiting, doula networks, CBOs straddling Medicaid + philanthropy)

• Payer-linked vendors (maternal wraparound bundles, care coordination startups)

• Policy-sensitive systems/MCOs (safety nets under OBBA squeeze, Medicaid MCOs recalibrating procurement)

Why maternal health?

Because if these models can prove ROI, survive audits, and contract cleanly, they will become the template for all SDOH-aligned care models. If they cannot, funders will retrench and the category will collapse under compliance and margin pressure.

Here are the maternal models reshaping Medicaid, Stars, and ROI in late 2025.

How We Scored

We asked one investor-grade question:

If we put $10M into this model, will it survive real-world financial, compliance, and operational pressure?

Each organization was evaluated across seven weighted dimensions:

1. ROI strength → Can they quantify avoided costs (e.g., NICU days prevented) with payer proxies?

2. Audit/MLR defensibility → Do services code, bill, and survive audit review?

3. Contracting fit → Can they plug into SPA/1115 waivers, Medicaid managed care, or bundles today?

4. Policy scalability → Can the model replicate across states, or is it locked in one policy environment?

5. Stars/CAHPS leverage → Do they move measures tied directly to plan revenue and reprocurement survival?

6. Operational readiness → Workforce, IT, and integration capacity to deliver at scale?

7. Financial durability → Runway and payer diversification to weather reimbursement lags and margin shocks?

Tiers of Fundability:

• Tier 1 (≥75): Procurement-ready; can defend margins today.

• Tier 2 (60–74): Pilot-worthy; needs seasoning before enterprise adoption.

• Tier 3 (<60): Watchlist; speculative, early-stage bets.

How to read this:

• This is pre-actuarial intelligence . Treat this as an early signal filter.

• Assumptions matter (NICU per-diem costs, churn, Stars lift all vary by market). We model conservatively, with transparent registries.

• Signals move quickly. SPA rules, audit trends, and denial codes shift quarter to quarter.

Part 1 (This Week): Profiles 1–7

This week we cover the first half of the Fundable 15:

• Wildflower Health

• Cayaba Care

• Mahmee

• Quilted Health

• Diana Health

• Oula Health

• Changent (Previously Nurse-Family Partnership)

Topline Results (Part I)

Tier 1 — Procurement ready

• Quilted Health (WA) — Midwifery + doula, actuarial validation, Regence bundle + MultiCare integration.

• Oula Health (NYC) — SPA-backed MMC subcontractor with published ROI band.

• Changent Previously Nurse-Family Partnership (Multi-state) — RCT-backed, Medicaid-covered across multiple states; unmatched audit pedigree.

Tier 2 — Emerging

• Mahmee (CA) — Explicit in Health Net manual; statewide Medi-Cal doula footprint; outcomes pending.

• Wildflower Health (NV) — OB-EMR-integrated subcontract with SilverSummit; pricing/ROI opaque.

• Diana Health (TN, FL, TX) — $100M+ funded hospital-anchored CNM/OB network; plan-level outcomes not public.

Tier 3 — On The Horizon

• Cayaba Care (PA) — Equity-focused vendor with IBX visibility; no pricing or denominators disclosed.

What We Learned

1. Evidence + billing beats PR. Oula, NFP, and Quilted have repeatable contracting logic; the others are still proving ROI.

2. Workforce is destiny. The best models fail if CNMs, RNs, or doulas can’t scale.

3. Stars is the tell. If a vendor can’t lift PPC/CAHPS with denominators, it won’t survive reprocurement.

Bottom line: Maternal models are multiplying; only those with claims-paid proof and audit-ready billing will endure.

Join us next week for coverage on the remaining eight (CenteringPregnancy through Bloomlife).

* UPDATE 9/16/2025 : Mahmee leadership shared helpful context after publication.

• Scale: 60M+ covered lives across public and private insurer contracts, serving thousands annually.

• Comprehensive Bundle: A first-of-its-kind ancillary care episode covering doula, RPM, lactation, mental & behavioral health, and nutrition.

• Data Asset: One of the largest independent EMR-based mother–baby datasets outside major systems, with enterprise-grade outcome reporting.

Scorecard placement: In this edition, Mahmee scored as a Tier 2 vendor. Our methodology is standardized: we evaluate organizations based on evidence that is publicly accessible and verifiable at the plan or policy level. That lens helps ensure comparability across all 15 organizations.

Forward-looking signal: Given Mahmee’s scale and infrastructure, the release of payer-validated outcomes from their dataset could quickly strengthen their positioning in future scorecards.

Upgrade to Premium for the playbooks, contracting clauses, and heat map our payer and investor readers use to decide where the next $10M flows.

Read more

Entity: CMS; state Medicaid agencies

What was wrong: Retention effects were masked by verification churn, eligibility noise, and overlapping policy changes, making attribution far less visible than implied.

Why wrong: I underestimated signal interference in public datasets.

Impact: Made the impact of correct strategies appear harder to prove than anticipated.

This analysis represents the author’s interpretation of publicly available information. All forward-looking assessments involve uncertainty and risk. Readers should conduct independent research and consult qualified professionals before making business or investment decisions. This content is for informational purposes only.

In This Edition

• 69% of disenrollments were paperwork-driven, not eligibility

• CMS’s new monthly verification files heighten churn risk

• H.R.1 delays some rules; ex parte + 30-day windows still required

• AZ reinstated ~25% procedural cases; VA >50% ex parte renewals

• Quick wins can preserve millions in margin per 100k members

• For Premium Subscribers: ROI math, cost tables, adoption maps, forward intel

During the unwinding, ≈69% of disenrollments were procedural (paperwork-driven).¹
States that executed strong ex parte renewals and address-hygiene processes had materially lower avoidable losses.

With CMS’s Aug 19, 2025 verification initiative, states now receive monthly reports flagging enrollees whose citizenship/immigration status cannot be confirmed in federal databases—raising churn risk.² ³

• *Virginia reported ~50–60% ex parte renewals in 2023; as of spring 2025, 29 states report >50% automation.*⁴ ⁵

• *Arizona documented ~25% of procedurally disenrolled members reinstated within the 90-day window in mid-2023.*⁶ ⁷

Execution differences are visible in public data.

Higher ex parte + rescissions = preserved revenue; lower rates = leakage.

The Problem

• Procedural disenrollment ≈ 69% of terminations during unwinding.¹

• H.R. 1 (2025) placed a moratorium through Oct 1, 2034 on select provisions of the 2024 Eligibility & Enrollment Final Rule (e.g., standardized reconsideration, pre-populated forms, mode parity).⁸

• Still enforceable:

  • Ex parte-first renewals²

  • ≥30-day response windows²

  • Returned-mail protections (standardized address-update duty required by Jan 1, 2027)⁸

• Verification push (Aug 2025): monthly immigration/citizenship validation = heightened procedural risk.² ³

The Fundable 15 | Interventions

How we scored:

We scored every retention strategy using five simple tests:

• Is there credible evidence it works?

• Does it show up in real enrollment or claims outcomes

• Does it align with CMS rules after H.R. 1?

• Has it been replicated in more than one state

• Can the ROI be calculated in dollars per member?

Only strategies that passed most of these checks became Candidates; others remain Conditional until new evaluations close the gaps.

Here are the 15 most material levers to reduce wrongful disenrollment and defend Medicaid revenue.

Quick Wins (0–90 Days)

1. Pre-populated renewals + 90-day reconsideration (AZ reinstated ~25% in 2023; state option under H.R. 1).

2. Address hygiene / NCOA workflows (stop wrongful terminations on returned mail).

3. Rescission dashboards (convert compliance data into CFO-ready margin metrics).

4. Auto re-enroll same MCO (≤120d, where waiver allowed; baseline 60d).

Structural Plays (6–12 Months)

5. High-automation ex parte renewals

6. 12-month CE (children, statutory)

7. 12-month CE (adults, 1115 waivers)

8. Navigator / CHW renewal assistance

9. 12-month postpartum coverage

Pipeline Bets (12–24 Months)

10. BHP bridges (NY, MN)

11. Oregon 24-mo CE pilots

12. Integrated eligibility hubs (e.g., VA, RI)

13. Marketplace facilitated enrollment

14. Medicaid↔CHIP child handoffs

15. Portal modernization

Takeaway:

• Do nothing: multi-million dollar leakage per 100k members.

• Quick wins: preserve a third to half in year one.

• Scale all 15: cut leakage significantly, stabilize continuity, and lead nationally on equity.

If you apply just one of these retention levers,

for example, pre-populated renewals with 90-day reconsideration you can protect ≈$3.2M per 100k members annually (at $530 PMPM).*

Many of you are already using these insights in real strategy.
That’s exactly why the index exists.
The Fundable 15 makes public signals legible, measurable, and useful.
Paid readers get the full toolkit: ROI math, maps, and forward signals.
If this work helps you, I invite you to join us in the paid tier.

The Fundable 15: Premium Insights

I. The Math

Read more

While the healthcare world celebrates Stars-linked platforms and generative AI for behavioral triage, someone still has to answer a simpler question:

Can peer support actually scale without compromising trust or blowing up margin?

Everyone’s selling human connection at scale. But scaling peer care requires more than good UX and case studies. It requires audit readiness, economic durability, and proof that members will keep showing up when the conversation is machine-scanned.

Today, we’re looking at Marigold Health, a company that’s spent nearly a decade trying to thread the needle between Medicaid-aligned peer support and NLP-powered behavioral risk escalation.

This is #F15

You’re reading a Fundable 15 Black Brief, my weekly drop on the most fundable, ROI-clear social care orgs flying under the radar.

Built for MA execs, funders, strategists, and M&A leads who know what Stars volatility feels like on a Monday.

This is Part 3 of 3 in our current series:
The New Infrastructure of Care

• Part 1: Solace Health ✓ (Medicare onboarding + Stars retention)

• Part 2: Wayspring ✓ (Delegated SUD infrastructure)

• Part 3: Marigold Health (Peer ops + NLP escalation logic)

What They Actually Do

Marigold Health offers chat-based peer support, augmented by a natural language processing (NLP) engine that flags behavioral risks in real time. The system routes alerts to clinical supervisors for review.

The idea: scale peer engagement while reducing the supervisory overhead needed to keep it safe, effective, and auditable.

👉🏽 Peer-led, HIPAA-compliant group chat
👉🏽 NLP risk scoring layered over text data
👉🏽 Contracts in MA, MD, NM (Medicaid + DSNP)
👉🏽 ~$17M raised since 2016
👉🏽 ~25,000 covered lives

The Intel

Why This Matters Now

CMS 2026 will demand documented audit trails for AI-enhanced decision systems. Any platform triggering care escalation (like Marigold’s NLP model) must be able to show:

• Escalation logic

• Override tracking

• Stars-linked attribution

Marigold has not publicly disclosed audit governance, override logic, or Stars attribution methodology. This absence limits what external evaluators can underwrite in terms of CMS 2026 readiness or Stars-aligned valuation.

The Embedded Tension:

Peer support works because it feels safe.

Marigold’s product thesis is built on a tightrope:

• On one side: Peer support works when people feel emotionally safe. That safety hinges on trust, confidentiality, and non-clinical tone.

• On the other side: CMS 2026 audit protocols demand transparency, documentation, override tracking, and the ability to defend decisions that influence care.

  
  Plans, vendors, and state programs will need to demonstrate:

  • What the model does

  • How it escalates

  • Who can override

  • Whether outcomes improve

This creates a fundamental tension:

The very moment peer support becomes auditable, it may become less trusted.
But if it isn’t auditable, it won’t be fundable or contractable under Stars-linked procurement.

To date, Marigold (like many in this space) has not publicly resolved this tension, as no override audits, escalation logic, or outcome attribution have been disclosed. If those elements remain undocumented beyond the sales deck, the market can’t underwrite them financially or operationally in this new reality.

The Data

Marigold’s PMPM is modeled at $150–180 (Full modeling breakdown below)

Resulting PMPM range: $150–180, assuming conservative member-to-peer ratios, intensive QA on NLP outputs, and moderate underutilization. In leaner staffing conditions, this could drop to ~$120 PMPM but current signals suggest a higher-cost baseline.

That means it is:

• 30–60% higher than peer support industry benchmarks

• With no public Stars or FUH/FUM attribution

• And no documented audit readiness to de-risk the NLP layer

Takeaway:

Marigold’s modeled PMPM is 20–50% above comparable programs. Unless Stars impact, cost offset, or trust-based retention can be demonstrated, the model exceeds payer tolerance in Medicaid and MA markets.

The Investment Thesis

The Bull Case

• CMS accepts NLP logic + override process in audit protocols

• NLP reduces supervisory costs enough to normalize PMPM

• Stars impact validated, and buyers embed Marigold in care ops stack

The Bear Case

• Stars impact remains anecdotal

• NLP logic lacks transparency → flagged in CMS audits

• Member trust erodes as escalations increase

• 2026 procurement cycle passes without compliance milestones met

The Fundable Verdict

Status: Not fundable. Possibly acquirable.

The value here is:

• Peer ops workflows

• MCO contracts

• Field-tested product-market fit in tough segments

But not the tech.

Strategic Value

Buyers with audit-ready Stars infrastructure could extract:

• Contracts

• Ops team

• Medicaid trust capital

…and sunset the NLP stack entirely.

Estimated acquisition range: $5M–$12M
Based on contract durability, margin potential, and ops quality, not IP.

Strategic Buyers

The buyers best suited for Marigold are the ones looking for audit-ready behavioral infrastructure that supports Stars performance, while already having clinical capacity and compliance infrastructure. What they’re missing is a scalable, trusted peer ops layer. Buyers like Devoted, CareBridge, Unite Us, Cityblock, SCAN, and PE platforms building Stars-aligned wraparound services make sense because they can absorb the contracts, fold in the workforce, and drop the tech stack.

Who doesn’t make sense: Tech-first startups, Series A growth plays, or innovation labs looking for differentiated IP.

The Quiet Move

Don’t buy it. Test it.

Pilot the NLP in a no-risk setting. Measure:

• Alert frequency

• Override rate

• FUH/FUM movement

• Member trust after escalation

If it works, negotiate for the team + contracts.
If not, pass cleanly.

What to Watch

Expansion Signals

• CMS eval or Stars-linked outcome release

• Override audit logic disclosed

• MA plan renewals or new DSNP launches

Red Flags

• Delay in audit logic publication

• Contract attrition in current states

• Leadership gaps in compliance, product, or payer engagement

The Bottom Line

Marigold is a real operator in a real space. But peer support + NLP still hasn’t proven it can move Stars metrics at scale without compliance friction or trust decay.

Verdict: Watchlist only.

Acquire the ops if you must. Retire the tech if you do.

Full PMPM breakdown of Marigold Health including staffing ratios, NLP QA costs, and margin risk zones below:

Estimated PMPM Cost Modeling Breakdown: Marigold Health

Estimated delivery cost of NLP-supported peer support services based on public info and industry benchmarks

Read more

Read more

📥 Download the full launch edition here:

F15launchedition

7.09MB ∙ PDF file

Download

Download

But that’s not how systems change.
And it’s definitely not how capital moves.

So I built The Fundable 15.

This is the first ROI-first watchlist of its kind—a briefing designed for funders, health plans, an…

Read more